PT2409963T - Utilização de derivados de ácidos gordos polinsaturados como medicamentos - Google Patents

Utilização de derivados de ácidos gordos polinsaturados como medicamentos

Info

Publication number
PT2409963T
PT2409963T PT107531584T PT10753158T PT2409963T PT 2409963 T PT2409963 T PT 2409963T PT 107531584 T PT107531584 T PT 107531584T PT 10753158 T PT10753158 T PT 10753158T PT 2409963 T PT2409963 T PT 2409963T
Authority
PT
Portugal
Prior art keywords
medicaments
derivatives
fatty acids
polyunsaturated fatty
polyunsaturated
Prior art date
Application number
PT107531584T
Other languages
English (en)
Inventor
Vicente Escribá Ruiz Pablo
Busquets Xaubet Xavier
Terés Jiménez Silvia
Barceló Coblijn Gwendolyn
Lladó Cañellas Victoria
Marcilla Etxenike Amaia
Laura Martín María
Higuera Urbano Mónica
Álvarez Martínez Rafael
Horacio López Daniel
Original Assignee
Lipopharma Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipopharma Therapeutics S L filed Critical Lipopharma Therapeutics S L
Publication of PT2409963T publication Critical patent/PT2409963T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT107531584T 2009-03-16 2010-03-15 Utilização de derivados de ácidos gordos polinsaturados como medicamentos PT2409963T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200900725A ES2345241B1 (es) 2009-03-16 2009-03-16 Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.

Publications (1)

Publication Number Publication Date
PT2409963T true PT2409963T (pt) 2017-02-15

Family

ID=42673244

Family Applications (2)

Application Number Title Priority Date Filing Date
PT107531584T PT2409963T (pt) 2009-03-16 2010-03-15 Utilização de derivados de ácidos gordos polinsaturados como medicamentos
PT162011324T PT3159329T (pt) 2009-03-16 2010-03-15 Utilização de derivados de ácidos gordos polinsaturados como medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT162011324T PT3159329T (pt) 2009-03-16 2010-03-15 Utilização de derivados de ácidos gordos polinsaturados como medicamentos

Country Status (19)

Country Link
US (7) US9161928B2 (pt)
EP (2) EP3159329B1 (pt)
JP (1) JP5904592B2 (pt)
KR (4) KR102233102B1 (pt)
CN (4) CN102356057A (pt)
AU (6) AU2010224749B2 (pt)
BR (1) BRPI1009860A8 (pt)
CA (1) CA2754963C (pt)
CL (1) CL2011002268A1 (pt)
DK (2) DK2409963T3 (pt)
ES (3) ES2345241B1 (pt)
HK (1) HK1232207A1 (pt)
HU (2) HUE051850T2 (pt)
MX (1) MX2011009614A (pt)
PL (1) PL2409963T3 (pt)
PT (2) PT2409963T (pt)
RU (1) RU2513995C2 (pt)
SI (1) SI3159329T1 (pt)
WO (1) WO2010106211A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
DK2493296T3 (en) 2009-10-30 2019-04-15 Retrotope Inc REMOVAL OF OXIDATIVE STRESS STATES WITH PUFA DERIVATIVES
WO2012148926A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
WO2012148930A2 (en) 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
US10058612B2 (en) 2011-04-26 2018-08-28 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Pufa 산화와 관련된 장애
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
EP3209637B1 (en) * 2014-10-21 2019-05-08 Universitat de les Illes Balears 2-hydroxy-triacylglycerol compounds for use in treating disease
US20180024150A1 (en) * 2015-03-06 2018-01-25 Niigata University Biomarker of dementia with lewy bodies
WO2017091279A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
GB201521085D0 (en) * 2015-11-30 2016-01-13 Biozep As Use
US11260042B2 (en) 2017-05-16 2022-03-01 Ability Pharmaceuticals S.L. Pharmaceutical combination for the treatment of cancer
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
CN112423843B (zh) 2018-06-15 2023-11-28 詹森药业有限公司 雷帕霉素类似物和其用途
CA3163680A1 (en) 2019-12-05 2021-06-10 David John O'neill Rapamycin analogs and uses thereof
ES2846824B2 (es) * 2020-01-29 2022-01-19 Univ Illes Balears Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
AU2021212330A1 (en) * 2020-01-29 2022-09-22 Universitat De Les Illes Balears Alpha-hydroxylated fatty-acid metabolites, medical uses of same and use as biomarkers
EP4103170A1 (en) 2020-02-10 2022-12-21 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer
US11779910B2 (en) 2020-02-21 2023-10-10 Biojiva Llc Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717816D0 (en) 1987-07-28 1987-09-03 Manchester Inst Science Tech Fabric testing apparatus
GB2218984B (en) * 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
JPH05974A (ja) * 1991-06-21 1993-01-08 Sagami Chem Res Center ハロゲン化不飽和アルキル化合物及びその前駆体
ES2161146B1 (es) * 1999-06-29 2002-07-01 Consejo Superior Investigacion Compuestos antimicrobianos, uso y metodo para inducir resistencia a infecciones de bacterias en plantas.
US6344574B1 (en) 2000-07-20 2002-02-05 The United States Of America As Represented By The Secretary Of Agriculture Solvent fractionation of chicken fat for making lipid compositions enriched in unsaturated fatty acid-containing triacylglycerols
DE10106660A1 (de) * 2001-02-12 2002-08-29 Celanese Ventures Gmbh Verfahren zur Herstellung von gamma-Linolensäure aus einer Ciliaten-Kultur durch Zusatz geeigneter Vorläufermoleküle zu dem Kulturmedium
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
WO2003084305A2 (en) * 2002-04-01 2003-10-16 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
MX2007006049A (es) 2004-11-19 2007-07-24 Martek Biosciences Corp Oxilipinas de acidos grasos poliinsaturados de cadena larga y metodos para elaborar y utilizar los mismos.
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
AU2006242914B2 (en) * 2005-05-04 2012-02-02 Pronova Biopharma Norge As New DHA derivatives and their use as medicaments
CN101213281B (zh) * 2005-05-04 2013-03-13 普罗诺瓦生物医药挪威公司 新的dha衍生物及其作为药物的用途
US8059805B2 (en) * 2005-06-30 2011-11-15 Emc Corporation Enhanced services provided using communication redirection and processing
AU2006269405B2 (en) * 2005-07-08 2013-01-17 Dsm Ip Assets B.V. Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
WO2007058523A1 (en) * 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
PT1800675E (pt) * 2005-12-23 2011-08-30 Nutricia Nv COMPOSIÇÃO CONTENDO ÁCIDOS GORDOS POLI-INSATURADOS, PROTEÍNAS E MANGANjS E/OU MOLIBDÉNIO PARA O MELHORAMENTO DA COMPOSIÇÃO DA MEMBRANA
CA2667211A1 (en) * 2006-11-01 2008-05-08 Pronova Biopharma Norge As Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar)
WO2008142482A2 (en) 2006-11-01 2008-11-27 Pronova Biopharma Norge As Omega-3 lipid compounds
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20080234377A1 (en) * 2007-03-23 2008-09-25 Martek Biosciences Corporation Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.

Also Published As

Publication number Publication date
DK2409963T3 (en) 2017-02-27
DK3159329T3 (da) 2020-11-09
CN109999018A (zh) 2019-07-12
AU2016238970A1 (en) 2016-11-03
RU2011141850A (ru) 2013-04-27
MX2011009614A (es) 2012-01-20
EP3159329B1 (en) 2020-08-12
KR102233102B1 (ko) 2021-03-26
US20190365690A1 (en) 2019-12-05
KR20110137365A (ko) 2011-12-22
KR20180021931A (ko) 2018-03-05
KR101833772B1 (ko) 2018-03-02
HK1232207A1 (zh) 2018-01-05
AU2010224749A1 (en) 2011-10-13
CA2754963C (en) 2022-02-08
BRPI1009860A2 (pt) 2016-03-08
AU2020205213B2 (en) 2021-02-25
AU2018203976B2 (en) 2019-06-06
CL2011002268A1 (es) 2012-01-27
US20120108550A1 (en) 2012-05-03
ES2820025T3 (es) 2021-04-19
AU2019226257A1 (en) 2019-09-26
RU2513995C2 (ru) 2014-04-27
CN106349058B (zh) 2020-01-14
CA2754963A1 (en) 2010-09-23
CN102356057A (zh) 2012-02-15
AU2019226257B2 (en) 2020-05-07
AU2020205214B2 (en) 2021-02-18
JP5904592B2 (ja) 2016-04-13
EP2409963B1 (en) 2017-01-04
KR20190018754A (ko) 2019-02-25
WO2010106211A1 (es) 2010-09-23
US20160158181A1 (en) 2016-06-09
CN106420686A (zh) 2017-02-22
ES2613606T3 (es) 2017-05-24
US9907772B2 (en) 2018-03-06
US20200352891A1 (en) 2020-11-12
BRPI1009860A8 (pt) 2019-12-17
ES2345241B1 (es) 2011-09-08
EP2409963A4 (en) 2013-10-02
PL2409963T3 (pl) 2017-05-31
US9763907B2 (en) 2017-09-19
AU2020205213A1 (en) 2020-07-30
KR20200024953A (ko) 2020-03-09
PT3159329T (pt) 2020-11-13
US11253497B2 (en) 2022-02-22
US20170035720A1 (en) 2017-02-09
EP3159329A1 (en) 2017-04-26
HUE051850T2 (hu) 2021-03-29
HUE032027T2 (en) 2017-08-28
CN106349058A (zh) 2017-01-25
US10201515B2 (en) 2019-02-12
US9161928B2 (en) 2015-10-20
ES2345241A1 (es) 2010-09-17
JP2012520344A (ja) 2012-09-06
EP2409963A1 (en) 2012-01-25
US20180085332A1 (en) 2018-03-29
AU2016238970B2 (en) 2018-03-08
CN106420686B (zh) 2020-05-22
AU2010224749B2 (en) 2016-07-07
AU2018203976A1 (en) 2018-06-21
AU2020205214A1 (en) 2020-07-30
SI3159329T1 (sl) 2021-01-29
US20160158180A1 (en) 2016-06-09
US9763906B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
HK1232207A1 (zh) 多不飽和脂肪酸的衍生物作為藥物的用途
EP2498602A4 (en) STABILIZED FORMULATIONS FROM FATTY ACIDS
EP2459189A4 (en) FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES
EP2480680A4 (en) PREPARATION OF FATTY ACID DERIVATIVES
EP2417246A4 (en) PRODUCTION OF FATTY ACID DERIVATIVES
EP2425007A4 (en) PREPARATION OF FATTY ACID ESTERS
EP2521447A4 (en) FATTY FATTY ACID DERIVATIVES AND USES THEREOF
EP2451907A4 (en) SYNTHESIS OF BIOFUEL ESTERS FROM DERIVATIVE UNSATURATED FATTY ACIDS
IL212112A0 (en) Production of modifird fatty acids in plants
EP2483233A4 (en) HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS
ZA201104036B (en) Fatty acids for use as a medicament
IL213354A (en) Alpha-monoclonal fatty acid alpha history for use as a drug
IL214887A0 (en) Fatty acid monoglyceride compositions
EP2560633B8 (en) Intravenous omega-3 fatty acid compositions & method of use
PT2528889T (pt) Processo para preparar e purificar ácidos gordos
SI2906587T1 (sl) Metode in sestave za izboljšano proizvodnjo maščobnih kislin in njihovih derivatov
GB201304550D0 (en) Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof
EP2726086A4 (en) COMPOSITIONS CONTAINING FATTY NITROACIDS
GB0904300D0 (en) Essential fatty acid compounds
AU2010903057A0 (en) Acetylenation of fatty acids
GB201021862D0 (en) Improvements in the manufacture of fatty acids
GB0810779D0 (en) Process for the conversion of fatty acids and derivatives thereof
GB0801878D0 (en) Process for the conversion of fatty acids and derivatives thereof